In its annual look ahead to the life sciences deal-making environment, PWC thinks 2024 will bring a continuation of what the biopharmaceutical sector has seen in 2023: an uptick in deal volume and valuations as the return to normalcy from the COVID-19 pandemic continues. The consulting firm expects between $225bn and $275bn of M&A activity in 2024, across all subsectors of the life sciences, but also predicts a better financing environment with interest rate risk beginning to moderate.
Looming patent expirations will continue to drive high-spending companies’ willingness to seek external innovation as a source for growth, the Pharmaceuticals and Life Sciences Deals Insights: 2024 Outlook report says
Key Takeaways
-
PWC anticipates a healthy environment for life sciences M&A activity in 2024, but thinks biopharma companies will emphasize quick accretion as much or more than revenue growth potential.
-
The metabolic/obesity space is emerging as a strong second to cancer as a top area of emphasis in deal-making, and PWC expects that trend to continue in 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?